Compass Therapeutics (CMPX) EBIAT (2023 - 2025)
Compass Therapeutics (CMPX) has disclosed EBIAT for 3 consecutive years, with -$15.7 million as the latest value for Q4 2025.
- Quarterly EBIAT fell 4.54% to -$15.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$66.5 million through Dec 2025, down 34.66% year-over-year, with the annual reading at -$66.5 million for FY2025, 34.66% down from the prior year.
- EBIAT hit -$15.7 million in Q4 2025 for Compass Therapeutics, down from -$14.3 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$7.8 million in Q1 2023 to a low of -$19.9 million in Q2 2025.
- Historically, EBIAT has averaged -$13.2 million across 3 years, with a median of -$13.2 million in 2023.
- Biggest YoY gain for EBIAT was 4.54% in 2025; the steepest drop was 54.19% in 2025.
- Year by year, EBIAT stood at -$13.4 million in 2023, then fell by 12.06% to -$15.0 million in 2024, then fell by 4.54% to -$15.7 million in 2025.
- Business Quant data shows EBIAT for CMPX at -$15.7 million in Q4 2025, -$14.3 million in Q3 2025, and -$19.9 million in Q2 2025.